Study of Predictive Factors of Chemoresistance in Ovarian Cancer

Rennes University Hospital13 enrolled

Overview

Epithelial ovarian cancer (EOC) has a poor prognosis. EOC management requires debulking surgery and chemotherapy based on taxol and carboplatine. Initial response is often good, but most often a recurrence occurred in the first 18 months. Early recurrence signs chemoresistance and palliative treatment. The study of predictive clinical or biological factors is required to adapt therapeutic and develop new treatments.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Ovarian Cancer

Interventions

Cancer treatmentPROCEDURE

Chemotherapy and laparoscopic surgery

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patient \> 18 years of age * patient with histological proven epithelial ovarian cancer Exclusion Criteria: * patients who can not give their own consent * patients without ovarian cancer

Locations (1)

LAVOUE

Rennes, France

Outcomes

Primary Outcomes

Chemoresistance defined by clinical recurrence

Time frame: 6 months after the end of chemotherapy

Chemoresistance defined by biological recurrence

Time frame: 6 months after the end of chemotherapy

Chemoresistance defined by radiological recurrence

Time frame: 6 months after the end of chemotherapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.